Biofrontera Inc. (BFRI)

Market Cap	6.50M
Revenue (ttm)	38.00M
Net Income (ttm)	-11.53M
Shares Out	9.45M
EPS (ttm)	-1.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220,334
Open	0.6600
Previous Close	0.7115
Day's Range	0.6401 - 0.7000
52-Week Range	0.5360 - 2.2200
Beta	0.30
Analysts	Strong Buy
Price Target	2.75 (+299.71%)
Earnings Date	Aug 13, 2025

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Oct 29, 2021
• Employees: 93
• Stock Exchange: NASDAQ
• Ticker Symbol: BFRI
• Website: https://www.biofrontera-us.com

Financial Performance

In 2024, Biofrontera's revenue was $37.32 million, an increase of 9.54% compared to the previous year's $34.07 million. Losses were -$17.76 million, -11.78% less than in 2023.

Analyst Summary

According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price target is $2.75.

Price Target

$2.75

(299.71% upside)

Analyst Consensus: Strong Buy